BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $42.00 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-24
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2026 was $42.00M, a 15.38% increase from fiscal 2025.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $36.40M, a 15.19% increase from fiscal 2024.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $31.60M, a 1.94% increase from fiscal 2023.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $31.00M, a 6.16% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|
| 2026-06-30 | $42.00M 10-K · filed 2026-08-24 | |
| 2025-06-30 | $36.40M 10-K · filed 2026-08-24 | |
| 2024-06-30 | $31.60M 10-K · filed 2026-08-24 | |
| 2023-06-30 | $31.00M 10-K · filed 2025-08-22 | $46.50M 10-K · filed 2023-08-23 |
| 2022-06-30 | $29.20M 10-K · filed 2024-08-22 | $82.30M 10-K · filed 2022-08-24 |
| 2021-06-30 | $70.50M 10-K · filed 2023-08-23 | |
| 2020-06-30 | $71.10M 10-K · filed 2022-08-24 | |
| 2019-06-30 | $31.70M 10-K · filed 2021-08-25 | |
| 2018-06-30 | $8.80M 10-K · filed 2020-08-26 | |
| 2017-06-30 | $5.00M 10-K/A · filed 2019-11-06 | |
| 2016-06-30 | $2.00M 10-K · filed 2018-08-27 | $1.60M 10-K · filed 2016-08-29 |
| 2015-06-30 | $2.30M 10-K · filed 2017-09-07 | |
| 2014-06-30 | $2.20M 10-K · filed 2016-08-29 | |
| 2013-06-30 | $1.50M 10-K · filed 2015-08-31 | |
| 2012-06-30 | $1.60M 10-K · filed 2014-08-29 | |
| 2011-06-30 | $1.00M 10-K · filed 2013-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |